Combination Regimen for Pretransplant Conditioning May Improve Outcomes for Patients With Multiple Myeloma
Results from a phase 3 open label trial (ClinicalTrials.gov Identifier: NCT01413178) published in The Lancet Haematology suggest that busulfan plus melphalan may result in longer progression-free survival (PFS) compared with melphalan alone in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation (HSCT). Patients with newly diagnosed multiple myeloma were accepted into the study…
